Identification of four novel associations for B-cell acute lymphoblastic leukaemia risk.
meta_analysis · Level I
Where this comes from
- Record sourced from PubMed, PMID 31767839.
- Also identified by DOI 10.1038/s41467-019-13069-6 and PMC identifier 6877561.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
There is increasing evidence for a strong inherited genetic basis of susceptibility to acute lymphoblastic leukaemia (ALL) in children. To identify new risk variants for B-cell ALL (B-ALL) we conducted a meta-analysis with four GWAS (genome-wide association studies), totalling 5321 cases and 16,666 controls of European descent. We herein describe novel risk loci for B-ALL at 9q21.31 (rs76925697, P = 2.11 × 10<sup>-8</sup>), for high-hyperdiploid ALL at 5q31.1 (rs886285, P = 1.56 × 10<sup>-8</sup>) and 6p21.31 (rs210143 in BAK1, P = 2.21 × 10<sup>-8</sup>), and ETV6-RUNX1 ALL at 17q21.32 (rs10853104 in IGF2BP1, P = 1.82 × 10<sup>-8</sup>). Particularly notable are the pleiotropic effects of the BAK1 variant on multiple haematological malignancies and specific effects of IGF2BP1 on ETV6-RUNX1 ALL evidenced by both germline and somatic genomic analyses. Integration of GWAS signals with transcriptomic/epigenomic profiling and 3D chromatin interaction data for these leukaemia risk loci suggests deregulation of B-cell development and the cell cycle as central mechanisms governing genetic susceptibility to ALL.
Medical subject headings
- Core Binding Factor Alpha 2 Subunit
- Genetic Predisposition to Disease
- Oncogene Proteins, Fusion
- Polymorphism, Single Nucleotide
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
- RNA-Binding Proteins
- bcl-2 Homologous Antagonist-Killer Protein